Puma Biotechnology Company Profile (NYSE:PBYI)

About Puma Biotechnology

Puma Biotechnology logoPuma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: PBYI
  • CUSIP:
Key Metrics:
  • Previous Close: $36.20
  • 50 Day Moving Average: $34.74
  • 200 Day Moving Average: $45.09
  • 52-Week Range: $36,818,000.00 - $19.74
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.04
  • P/E Growth: 0.11
  • Market Cap: $1.33B
  • Outstanding Shares: 36,818,000
  • Beta: 0.35
Profitability:
  • Return on Equity: -179.99%
  • Return on Assets: -141.40%
Debt:
  • Current Ratio: 3.12%
  • Quick Ratio: 3.12%
Additional Links:
Companies Related to Puma Biotechnology:

Analyst Ratings

Consensus Ratings for Puma Biotechnology (NYSE:PBYI) (?)
Ratings Breakdown: 3 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $76.33 (110.87% upside)

Analysts' Ratings History for Puma Biotechnology (NYSE:PBYI)
Show:
DateFirmActionRatingPrice TargetDetails
1/18/2017Credit Suisse GroupReiterated RatingOutperformView Rating Details
1/3/2017Citigroup Inc.Set Price TargetBuy$88.00View Rating Details
11/30/2016Stifel NicolausReiterated RatingBuy$88.00View Rating Details
11/16/2016RBC Capital MarketsReiterated RatingSector PerformView Rating Details
11/15/2016Cowen and CompanyReiterated RatingMarket PerformView Rating Details
11/14/2016J P Morgan Chase & CoSet Price TargetBuy$89.00View Rating Details
3/29/2016Royal Bank of CanadaDowngradeOutperform -> Sector Perform$103.00 -> $36.00View Rating Details
1/5/2016Berenberg BankUpgradeHold -> BuyView Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Puma Biotechnology (NYSE:PBYI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017        
2/27/2017($1.92)N/AView Earnings Details
5/10/2016Q1($1.99)($1.28)ViewN/AView Earnings Details
2/29/2016Q4($1.95)($1.23)ViewN/AView Earnings Details
11/9/2015Q3($1.84)($1.87)ViewN/AView Earnings Details
8/10/2015Q2($1.55)($1.13)ViewN/AView Earnings Details
5/11/2015Q1($1.25)($1.02)ViewN/AView Earnings Details
3/2/2015($1.15)($1.59)ViewN/AView Earnings Details
11/10/2014($1.27)($1.19)ViewN/AView Earnings Details
8/11/2014Q214($0.66)($1.05)ViewN/AView Earnings Details
5/12/2014($0.48)($0.67)ViewN/AView Earnings Details
3/3/2014Q413($0.49)($0.46)ViewN/AView Earnings Details
4/1/2013Q413($0.70)($0.25)ViewN/AView Earnings Details
11/14/2012Q312($1.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Puma Biotechnology (NYSE:PBYI)
Current Year EPS Consensus Estimate: $-8.12 EPS
Next Year EPS Consensus Estimate: $-7.18 EPS

Dividends

Dividend History for Puma Biotechnology (NYSE:PBYI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Puma Biotechnology (NYSE:PBYI)
Insider Ownership Percentage: 22.70%
Institutional Ownership Percentage: 80.98%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/1/2017Robert CharnasInsiderSell3,008$31.83$95,744.64View SEC Filing  
1/20/2017Alan H AuerbachInsiderSell10,202$33.24$339,114.48View SEC Filing  
1/20/2017Richard Paul BryceSVPSell2,293$33.24$76,219.32View SEC Filing  
7/6/2015Richard Paul BryceSVPSell3,000$110.03$330,090.00View SEC Filing  
11/8/2013Adage Capital Partners Gp Llcmajor shareholderBuy22,549$38.92$877,607.08View SEC Filing  
11/5/2013Adage Capital Partners Gp Llcmajor shareholderBuy280,700$39.60$11,115,720.00View SEC Filing  
10/9/2013Adage Capital Partners Gp Llcmajor shareholderBuy140,900$40.44$5,697,996.00View SEC Filing  
12/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy29,560$19.00$561,640.00View SEC Filing  
12/12/2012Adage Capital Partners Gp LlcMajor ShareholderBuy30,400$19.00$577,600.00View SEC Filing  
12/11/2012Adage Capital Partners Gp LlcMajor ShareholderBuy140,040$18.98$2,657,959.20View SEC Filing  
10/24/2012Thomas MalleyDirectorBuy10,000$16.00$160,000.00View SEC Filing  
10/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy610,000$16.00$9,760,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Puma Biotechnology (NYSE:PBYI)
DateHeadline
News IconPuma Biotechnology Inc PBYI Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NYSE:PBYI)
www.bioportfolio.com - February 26 at 6:11 PM
News IconShares in Focus: Puma Biotechnology, Inc. (NASDAQ:PBYI) - The Standard (NYSE:PBYI)
6milestandard.com - February 24 at 8:42 AM
News IconAnalysts Peer Into Their Crystal Balls For Puma Biotechnology Inc (NYSE:PBYI): Where Is It headed? - Winfield Review (NYSE:PBYI)
winfieldreview.com - February 24 at 8:42 AM
prnewswire.com logoResearch Reports Coverage on Biotech Stocks -- Puma Biotechnology, Dipexium Pharma, BioCryst Pharma, and CTI ... - PR Newswire (press release) (NYSE:PBYI)
www.prnewswire.com - February 24 at 8:42 AM
News IconFiscal Year Earnings Estimate on Puma Biotechnology Inc(PBYI) - Money Flow Index & Trends (NYSE:PBYI)
www.moneyflowtrends.com - February 24 at 8:42 AM
News IconEarnings According to Analysts for Puma Biotechnology Inc (NYSE:PBYI)? - Aiken Advocate (NYSE:PBYI)
aikenadvocate.com - February 20 at 6:24 PM
News IconNumbers in Review for Puma Biotechnology Inc. (PBYI) - Midway Monitor (NYSE:PBYI)
midwaymonitor.com - February 18 at 11:41 AM
nasdaq.com logoNotable Friday Option Activity: PBYI, VMI, ASH (NYSE:PBYI)
www.nasdaq.com - February 17 at 4:48 PM
News IconIs The Sell-Side Predicting That Puma Biotechnology Inc (NYSE:PBYI) Will Move Higher? - Winfield Review (NYSE:PBYI)
winfieldreview.com - February 17 at 8:08 AM
News IconShare Tracker: Puma Biotechnology, Inc. (NASDAQ:PBYI) - Midway Monitor (NYSE:PBYI)
midwaymonitor.com - February 15 at 4:12 AM
finance.yahoo.com logoPuma Biotechnology to Present at RBC Capital Markets Healthcare Conference (NYSE:PBYI)
finance.yahoo.com - February 14 at 11:09 PM
finance.yahoo.com logoPuma Biotechnology to Present at LEERINK Partners Global Healthcare Conference (NYSE:PBYI)
finance.yahoo.com - February 8 at 8:06 PM
News IconStock Focus: Watching the Levels for Puma Biotechnology, Inc. (NASDAQ:PBYI) - Baxter Review (NYSE:PBYI)
baxternewsreview.com - February 7 at 8:14 PM
News IconImpact Score Of Puma Biotechnology Inc (NYSE:PBYI) At 0 | Stock ... - Stock Observer (NYSE:PBYI)
www.thestockobserver.com - February 7 at 12:12 AM
News IconPuma Biotechnology Inc (NYSE:PBYI) Investor Investigation over potential Wrongdoing (NYSE:PBYI)
www.satprnews.com - February 3 at 7:57 PM
thestreet.com logoBiotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results? (NYSE:PBYI)
www.thestreet.com - February 3 at 7:57 PM
News IconStock Vacillating as Volatility Hits a High Point For Puma Biotechnology, Inc. (NYSE:PBYI) - Wall Street Beacon (NYSE:PBYI)
wsbeacon.com - February 1 at 1:10 AM
News IconF-Score Review on Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) - The Tribune (NYSE:PBYI)
lakecitytribune.com - January 30 at 12:37 AM
News IconBullish Target Of Puma Biotechnology Inc (NYSE:PBYI) At $89 ... - Stock Observer (NYSE:PBYI)
www.thestockobserver.com - January 27 at 12:32 AM
News IconNYSE:PBYI Investor Alert: Investigation over potential Wrongdoing at Puma Biotechnology Inc (NYSE:PBYI)
www.groundreport.com - January 25 at 11:29 PM
News IconSEE REMARKS of Puma Biotechnology Inc (NASDAQ:PBYI), Eyler Charles R, sells 820 shares worth $27,253 (NYSE:PBYI)
empowerednews.net - January 25 at 12:56 AM
News IconTakara Bio USA, Inc. and TeselaGen Biotechnology, Inc. Release a Powerful New Primer Tool for Easy Design of In-Fusion Cloning Experiments (NYSE:PBYI)
www.bio-medicine.org - January 24 at 7:55 PM
News IconEarnings in Full Force, Analysts Take Aim at Puma Biotechnology Inc (NYSE:PBYI) - Wall Street Beacon (NYSE:PBYI)
wsbeacon.com - January 24 at 8:46 AM
News IconPriming The Pump: Stock Volatility Spotted in Puma Biotechnology, Inc. (NYSE:PBYI) - Wall Street Beacon (NYSE:PBYI)
wsbeacon.com - January 24 at 8:46 AM
News IconWhat do the Charts Say About Shares of Puma Biotechnology Inc. (PBYI) - Sherwood Daily (NYSE:PBYI)
sherwooddaily.com - January 21 at 6:53 PM
News IconPuma Biotechnology Inc (NASDAQ:PBYI) Valuation According To ... - UK Market News (NYSE:PBYI)
www.ukmarketnews.co.uk - January 20 at 7:58 PM
News IconStock Watch: Indicators in View for Puma Biotechnology Inc. (PBYI) - Springdale Times (NYSE:PBYI)
springdaletimes.com - January 20 at 7:58 PM
News IconAmplified Volatility Spotted in Shares of Puma Biotechnology, Inc. (NYSE:PBYI) - Wall Street Beacon (NYSE:PBYI)
wsbeacon.com - January 20 at 7:58 PM
News IconPuma Biotechnology Inc (NYSE:PBYI) Rating Fixed At 1.67 - Stock Observer (NYSE:PBYI)
www.thestockobserver.com - January 19 at 5:47 AM
News IconPuma Biotechnology Inc (PBYI) : Kessler Investment Group Boosts Position by $687668 - Highland Mirror (NYSE:PBYI)
www.highlandmirror.com - January 19 at 5:47 AM
News IconPuma Biotechnology Inc PBYI Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NYSE:PBYI)
www.bioportfolio.com - January 18 at 7:44 PM
4-traders.com logoInvestigation for Investors with Losses from Their Investment in Shares of Puma Biotechnology Inc (NYSE:PBYI) (NYSE:PBYI)
www.4-traders.com - January 18 at 7:44 PM
News IconWill The Needle Move For Puma Biotechnology Inc (NYSE:PBYI) Shares This Earnings Season? - Wall Street Beacon (NYSE:PBYI)
wsbeacon.com - January 17 at 7:31 PM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Puma Biotechnology, Inc. (NYSE:PBYI) - Wall Street Beacon (NYSE:PBYI)
wsbeacon.com - January 17 at 7:31 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Puma Biotechnology Inc (NYSE:PBYI) - Wall Street Beacon (NYSE:PBYI)
wsbeacon.com - January 13 at 12:47 AM
marketexclusive.com logoPUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Other ... - Market Exclusive (NYSE:PBYI)
marketexclusive.com - January 10 at 12:48 AM
finance.yahoo.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of Puma Biotechnology, Inc. - PBYI - Yahoo Finance (NYSE:PBYI)
finance.yahoo.com - January 10 at 12:48 AM
News IconPuma Biotechnology Inc (NYSE:PBYI) Impact Score At 0 - Stock Observer (NYSE:PBYI)
www.thestockobserver.com - January 8 at 6:51 PM
baystreet.ca logoPuma Biotechnology (PBYI) Jumps on Newest Drug News (NYSE:PBYI)
www.baystreet.ca - January 7 at 12:53 AM
streetinsider.com logoPuma Biotech (PBYI) Expands Cohort on Lead Drug Candidate PB272 (NYSE:PBYI)
www.streetinsider.com - January 7 at 12:53 AM
publicnow.com logoPuma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients (NYSE:PBYI)
us.rd.yahoo.com - January 7 at 12:53 AM
prnewswire.com logoResearch Reports Initiation on Biotech Stocks -- Puma ... - PR Newswire (press release) (NYSE:PBYI)
www.prnewswire.com - January 6 at 7:51 PM
streetinsider.com logoPuma Biotech (PBYI) Expands Cohort on Lead Drug Candidate PB272 - StreetInsider.com (NYSE:PBYI)
www.streetinsider.com - January 6 at 7:51 PM
News IconPuma Biotechnology Inc (NYSE:PBYI) Bullish Target At $89 - Stock Observer (NYSE:PBYI)
www.thestockobserver.com - January 5 at 6:02 AM
stocksdaily.net logoPuma Biotechnology Inc (NYSE:PBYI) Analysts EPS Target At $-2.02 - Stocks Daily (NYSE:PBYI)
www.stocksdaily.net - January 3 at 11:45 PM
finance.yahoo.com logoPuma Biotechnology to Present at J.P. Morgan Healthcare Conference (NYSE:PBYI)
finance.yahoo.com - January 3 at 11:45 PM
News IconGrowth Story Unfolding for Puma Biotechnology, Inc. (NYSE:PBYI) - Prospect Journal (NYSE:PBYI)
prospectjournal.com - January 2 at 6:58 PM
News IconNews Impact Score Of Puma Biotechnology Inc (NYSE:PBYI) At 0 - Stock Observer (NYSE:PBYI)
www.thestockobserver.com - January 1 at 7:24 PM
News IconPuma Biotechnology Inc (NYSE:PBYI) Valuation According To Analysts - UK Market News (NYSE:PBYI)
www.ukmarketnews.co.uk - December 26 at 6:30 PM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: Puma Biotechnology, Inc. (NYSE:PBYI) - Prospect Journal (NYSE:PBYI)
prospectjournal.com - December 26 at 6:30 PM

Social

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBYI."

Where is Puma Biotechnology's stock going? Where will Puma Biotechnology's stock price be in 2017?

7 equities research analysts have issued 12 month price targets for Puma Biotechnology's shares. Their predictions range from $36.00 to $111.00. On average, they expect Puma Biotechnology's stock price to reach $76.33 in the next twelve months.

When will Puma Biotechnology announce their earnings?

Puma Biotechnology is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

Who owns Puma Biotechnology stock?

Puma Biotechnology's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (9.40%), Orbimed Advisors LLC (6.18%), Janus Capital Management LLC (6.01%), State Street Corp (5.29%), Tourbillon Capital Partners L.P. (1.22%) and Teachers Retirement System of The State of Kentucky (0.17%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Richard Paul Bryce and Robert Charnas.

Who sold Puma Biotechnology stock? Who is selling Puma Biotechnology stock?

Puma Biotechnology's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Orbimed Advisors LLC, Janus Capital Management LLC, Oxford Asset Management, Federated Investors Inc. PA, State Board of Administration of Florida Retirement System and Putnam Investments LLC. Company insiders that have sold Puma Biotechnology stock in the last year include Alan H Auerbach, Richard Paul Bryce and Robert Charnas.

Who bought Puma Biotechnology stock? Who is buying Puma Biotechnology stock?

Puma Biotechnology's stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Tourbillon Capital Partners L.P., Teachers Retirement System of The State of Kentucky, Numeric Investors LLC, Highland Capital Management LP, Paulson & CO. Inc., A.R.T. Advisors LLC and Perceptive Advisors LLC.

How do I buy Puma Biotechnology stock?

Shares of Puma Biotechnology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Puma Biotechnology stock cost?

One share of Puma Biotechnology stock can currently be purchased for approximately $36.20.

Puma Biotechnology (NYSE:PBYI) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Puma Biotechnology (NYSE:PBYI)

Earnings History Chart

Earnings by Quarter for Puma Biotechnology (NYSE:PBYI)

Dividend History Chart

Dividend Payments by Quarter for Puma Biotechnology (NYSE:PBYI)

Last Updated on 2/27/2017 by MarketBeat.com Staff